Navigation Links
Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China
Date:2/24/2011

NEW YORK and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN; NYSE: SNY) today announced that it has completed the previously announced acquisition of BMP Sunstone Corporation (NASDAQ: BJGP). At a special meeting of stockholders held today, BMP Sunstone stockholders approved the adoption of the merger agreement among BMP Sunstone, sanofi-aventis and Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, dated October 28, 2010, as amended on November 22, 2010.  Following the special meeting, the merger was completed.

Pursuant to the merger agreement, BMP Sunstone stockholders will receive USD 10.00 per share in cash for each share of common stock they owned immediately prior to the effective time of the merger. Stockholders of record will receive a letter of transmittal and instructions on how to surrender their shares of BMP Sunstone common stock to the paying agent in exchange for the merger consideration.

With the closing of the merger, BMP Sunstone common stock will no longer trade on the NASDAQ Global Market following today's market close and will be delisted.

Morgan, Lewis & Bockius LLP served as counsel to BMP Sunstone. Stephens Inc. acted as financial advisor to BMP Sunstone.  Shearman & Sterling LLP served as counsel to sanofi-aventis. Morgan Stanley acted as financial advisor to sanofi-aventis.

About BMP SunstoneBMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone the Company manufactures leading pediatric and women's health products sold in pharmacies throughout the country. The Company also markets a portfolio of products under exclusive multi-year licenses into China, primarily focused on women's health and pediatrics, as well as provides pharmaceutical dist
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanofi-aventis to Acquire Genzyme for $74.00 in Cash Per Share Plus Contingent Value Right
2. Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers
3. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
4. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
5. Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
6. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
7. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
8. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
9. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
10. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
11. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... Kinex Pharmaceuticals announced today that the first ... Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin ... potent inhibitory activity against a broad panel of brain ... Temozolomide (T98G), the most widely used chemotherapy for the ... mouse model, KX2-361 consistently clears brain tumors after 4 ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... in Patients Reduces,Severity of Adult Leukaemia , Copenhagen, ... company, announced today that SPC2996, the,Company's new RNA ... in an initial Phase I/II clinical study in ... were reported,this week at the 2007 Annual Meeting ...
... Shows Safety and Pharmacokinetics Similar to IV ... N.J., June 06, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated ... show the Company's lead anti-cancer drug,Genasense(R) (oblimersen ... subcutaneous (SC) injection, as well,as by brief ...
Cached Medicine Technology:Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 2Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 3Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 4Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 5Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 6Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 7Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 8Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia 9Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 2Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 3Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection 4
(Date:12/24/2014)... 2014 New studies reveal that women under ... related depression (March 6, 2014, JAMA Otolaryngology*). And although many ... (about 50 percent according to recent polls) facing hearing loss ... a person feels and relates to the world. People who ... also made by way of:, , self-confidence ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, ... and launched a site-wide wedding gown promotion. , ... in a more unexpected way, the collection should be a ... the global market, and they are available with custom service. ... at discounted prices, up to 75% off; most of them ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... The holidays can be a challenge for people who suffer ... drinks. "This is the season in which many people ... David Dodick, chair of the American Migraine Foundation, said in ... think through food and beverage choices, to help reduce the ... of neurology at the Mayo Clinic in Scottsdale, Ariz. , ...
(Date:12/24/2014)... Adults who experienced childhood abuse or neglect have ... study published online Dec. 24 in the journal ... long-lasting effects, like associated medical and psychological conditions ... director of behavioral medicine at Montefiore Headache Center ... news release. "When managing patients with migraine, ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2
... consumer,employer and labor organizations today announced a ... health insurers on principles,to guide how health ... to consumers., The "Patient Charter for ... today creates a national set of principles,to ...
... Turns Assets from Retirement Plans Into Guaranteed Income for ... ... NEW YORK, April 1, 2008 AXA Equitable Life,Insurance Company, ... variable annuity -- Crossings(SM): My Lifetime,IRA(SM), designed specifically as a ...
... disease , , TUESDAY, April 1 (HealthDay News) -- The weight-loss ... buildup of arterial plaque that,s connected with carrying too much ... evidence that the drug actually slowed disease progression, although it ... in arteries. , Acomplia also showed a high rate ...
... drug discovery and the pharmaceutical industry currently underway will ... to a top researcher at the National Institutes of ... drug research and development. , According to ... Center (NCGC), both industry and academia welcome more cooperation ...
... 2008) A catheter-mounted device that acts like a ... heart valve is not only reducing the abnormal backflow ... atrium, it is helping to shrink the enlarged, overworked ... surgery. These are the one-year findings in a small ...
... A new study has found that an x-ray dye ... prevent renal injury during percutaneous coronary intervention (PCI) in ... it made no difference in the need for dialysis ... the Contrast Media and Nephrotoxicity Following Coronary Revascularization by ...
Cached Medicine News:Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 2Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 3Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 4Health News:Consumers, Health Care Purchasers, Physicians, and Health Insurers Announce Agreement on Principles to Guide Physician Performance Reporting 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 3Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 4Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 6Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 7Health News:Obesity Drug Shows Mixed Success Against Atherosclerosis 2Health News:Obesity Drug Shows Mixed Success Against Atherosclerosis 3Health News:Business of drug development on verge of great change 2Health News:Catheter repair of mitral valve improves heart size, symptoms 2Health News:Catheter repair of mitral valve improves heart size, symptoms 3Health News:Iso-osmolar X-ray dye falters in PCI study 2Health News:Iso-osmolar X-ray dye falters in PCI study 3
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
Medicine Products: